Breaking News
Get 50% Off 0
📈 Q2 Earnings Alert! Plan ahead with key data on upcoming stock reports - all in 1 place
See Calendar
Close

Donga Socio Holdings (000640)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
114,000 0    0.00%
05:33:30 - Delayed Data. Currency in KRW
Type:  Equity
Market:  South Korea
ISIN:  KR7000640003 
  • Volume: 5,410
  • Bid/Ask: 113,600 / 114,100
  • Day's Range: 113,500 - 115,600
Donga Socio Holdings 114,000 0 0.00%

Donga Socio Holdings Company Profile

 
Get an in-depth profile of Donga Socio Holdings, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

5530

Equity Type

ORD

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical trial to treat obesity; and STP0404 for the treatment of AIDS. It also provides medical devices and equipment; healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and cosmetics; health functional food; contract development and manufacturing organization for biosimilar and pharmaceutical products, and oligonucleotide therapeutics; functional sports drinks under the POCARI SWEAT brand; logistics and fulfillment services; glass bottles, PET bottles, aluminum and plastic caps, and paper packaging boxes; mineral and carbonated water, and mixed drinks; and IT and construction services. In addition, the company is involved in engineering; cargo, courier, and automobile transport arrangement; transportation warehousing and leasing; real estate development; agricultural product distribution; management consulting; business management; and architectural, electric work, fire protection, and housing contracting services. Dong-A Socio Holdings Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

Contact Information

Address 64, Cheonho-daero Dongdaemun-gu
Seoul, 02587
South Korea
Phone 82 2 920 8114
Fax 82 2 923 8224

Top Executives

Name Age Since Title
Shin-Ho Kang 97 - Honorary Chairperson
Kyoung Bae Kwon - 2021 Independent Non-Executive Outside Chairman
Seung Hyun Ko - 2021 Executive Director, CFO & Head of Management Support Office
Min-Young Kim 52 2017 CEO & Executive Director
Young-Sam Keum - 2022 Independent Outside Director
Se-Won Kwon - 2022 Independent Outside Director
Yeon-seok Jeong - 2025 Non-Executive Director
Hyun-Min Lee 55 2025 Executive Director & Head of Business Planning Office
Young-Jin Chung - 2024 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

000640 Comments

Write your thoughts about Donga Socio Holdings
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email